HDAC10 and primary cutaneous T-cell non-Hodgkin lymphoma: However, the response to the specific HDAC10i in targeted therapies may depend not only on the level of HDCA10 expression itself in a given patient but also on HDAC10 activity, and those may be influenced by specific genetic mutations observed in CTCL patients, particularly those affecting pathways that HDAC10 regulates or interacts with.